UroGen Pharma UGN-103 Achieves 94.5% Durability of Response at Six Months
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
UroGen Pharma announced UGN-103 achieved a 94.5% durability of response at six months by Kaplan-Meier estimate, in the ongoing Phase 3 UTOPIA trial of UGN-103 for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. The six-month results from UTOPIA are generally consistent with the 91.9% six-month DOR observed with Zusduri for intravesical therapy in its pivotal ENVISION trial. Zusduri is the first and only treatment approved by the FDA for adult patients with recurrent LG-IR-NMIBC. Based on the consistency of UTOPIA data with the results of the ENVISION trial studying Zusduri in patients meeting the same eligibility criteria and alignment with the FDA, UroGen remains on track to submit a new drug application for UGN-103 in the third quarter of 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy URGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on URGN
Wall Street analysts forecast URGN stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.460
Low
31.00
Averages
40.25
High
55.00
Current: 29.460
Low
31.00
Averages
40.25
High
55.00
About URGN
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Superstring Capital Reduces Stake in UroGen Pharma
- Stake Reduction Details: Superstring Capital reduced its stake in UroGen Pharma by 330,983 shares in Q1 2026, with an estimated transaction value of $6.64 million, indicating ongoing confidence despite the holding dropping to 4.98% of AUM.
- Market Performance Analysis: UroGen Pharma's stock has surged over 600% in the past year, currently priced at $28.89, significantly outperforming the S&P 500's 28% increase, showcasing its strong position in the biotech sector.
- Clinical Progress Highlights: UroGen recently reported that its newly approved bladder cancer therapy ZUSDURI achieved a 64.5% probability of remaining disease-free at three years, while UGN-103's Phase 3 trial showed a 94.5% six-month duration of response, underscoring the clinical potential of its product pipeline.
- Long-term Investment Outlook: Despite the stake reduction, UroGen remains one of Superstring's top five holdings, and the key question for investors will be whether UroGen can convert its clinical momentum into a sustainable oncology franchise, especially with UGN-103's patent protection expected to last until 2041.
See More
Superstring Capital Reduces Stake in UroGen Pharma
- Stake Reduction Details: Superstring Capital sold 330,983 shares of UroGen Pharma in Q1, with an estimated transaction value of $6.64 million, indicating a potential decrease in confidence in the company.
- Position Value Decline: The quarter-end value of Superstring's holdings in UroGen fell by $9.86 million, reflecting the dual impact of trading activity and stock price fluctuations, with total holdings now at 387,371 shares valued at $6.96 million.
- Company Strategy and Market Position: UroGen Pharma focuses on innovative therapies, particularly for non-muscle invasive bladder cancer, and despite the stake reduction, it remains one of Superstring's top five holdings, accounting for about 5%, highlighting its significance in the rapidly growing biotech market.
- Clinical Progress and Investor Interest: UroGen's recently approved bladder cancer therapy ZUSDURI demonstrated a 64.5% probability of three-year disease-free survival, and promising Phase 3 data for UGN-103 is on track for NDA submission in Q3 2026, prompting investors to consider whether the company can leverage clinical momentum into a sustainable oncology franchise.
See More
Healthcare Stocks Rise 0.8% on NYSE Healthcare Index
- Healthcare Sector Recovery: On Wednesday afternoon, the NYSE Healthcare Index rose by 0.8%, indicating a gradual restoration of investor confidence in the healthcare sector, likely driven by an overall improvement in market sentiment.
- Market Rebound Signs: The increase in healthcare stocks suggests that despite economic uncertainties, investors remain optimistic about the long-term growth potential of the healthcare industry, particularly in areas like drug development and medical technology innovation.
- Increased Investor Attention: As the healthcare sector continues to evolve, heightened investor interest may lead to increased capital inflows into this area, further driving stock prices upward.
- Optimistic Industry Outlook: The growth potential of the healthcare sector is attracting more investor attention, especially against the backdrop of rising global health demands, with expectations for increased investments to support innovation and expansion in the future.
See More
Urogen Pharma CMO Mark Schoenberg Sells Shares
- Executive Sell-off: Urogen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares on May 8, 2026, which may indicate a cautious outlook on the company's future performance, potentially negatively impacting investor confidence.
- Market Reaction: Such executive sell-offs are often interpreted by the market as a sign of unease regarding the company's prospects, which could lead to short-term stock price volatility, prompting investors to closely monitor subsequent developments to assess potential risks.
- Shareholding Changes: This sale may affect Schoenberg's ownership stake, and investors should pay attention to any subsequent changes in his holdings to gauge his confidence in the company's future.
- Transparency Concerns: The executive's sell-off raises market concerns about the company's governance transparency, which may lead investors to question the management team's decision-making capabilities.
See More
UroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth
- ZUSDURI Revenue Surge: UroGen Pharma reported $29.2 million in ZUSDURI revenue for Q1 2026, representing over 100% quarter-over-quarter growth, indicating a significant increase in market acceptance and suggesting substantial future sales potential.
- Increase in Prescribers: By the end of Q1, UroGen had 256 unique prescribers, up from 102 at year-end, with repeat prescribers rising from 32 to 103, demonstrating accelerated market penetration and growing physician engagement.
- Improved Financial Performance: The company achieved total revenue of $51 million in Q1, a substantial increase from $20.3 million in the same quarter of 2025, although it reported a net loss of $23.6 million, which is an improvement from a loss of $43.8 million a year earlier, indicating a gradual financial recovery.
- Optimistic Future Outlook: Management expects continued strong growth throughout 2026, although formal sales guidance for ZUSDURI is not provided; however, net product revenues for JELMYTO are projected to be between $97 million and $101 million, reflecting confidence in the product line.
See More
UroGen Pharma Q1 Earnings Beat Expectations
- Earnings Highlights: UroGen Pharma reported a Q1 GAAP EPS of -$0.47, beating expectations by $0.01, indicating a slight improvement in financial performance despite ongoing losses.
- Revenue Surge: The company achieved Q1 revenue of $51 million, reflecting a remarkable 151.2% year-over-year increase, surpassing estimates by $6.18 million, which underscores strong market demand for its products.
- Future Guidance: UroGen expects net product revenue for JELMYTO in 2026 to range between $97 million and $101 million, implying a year-over-year growth rate of approximately 3% to 7% over the $94 million reported in 2025, indicating a stable market outlook.
- Expense Projections: The company anticipates full-year 2026 operating expenses to be between $240 million and $250 million, including non-cash share-based compensation expenses of $20 million to $24 million, highlighting the cost pressures associated with business expansion.
See More
Superstring Capital Reduces Stake in UroGen Pharma
- Stake Reduction Details: Superstring Capital reduced its stake in UroGen Pharma by 330,983 shares in Q1 2026, with an estimated transaction value of $6.64 million, indicating ongoing confidence despite the holding dropping to 4.98% of AUM.
- Market Performance Analysis: UroGen Pharma's stock has surged over 600% in the past year, currently priced at $28.89, significantly outperforming the S&P 500's 28% increase, showcasing its strong position in the biotech sector.
- Clinical Progress Highlights: UroGen recently reported that its newly approved bladder cancer therapy ZUSDURI achieved a 64.5% probability of remaining disease-free at three years, while UGN-103's Phase 3 trial showed a 94.5% six-month duration of response, underscoring the clinical potential of its product pipeline.
- Long-term Investment Outlook: Despite the stake reduction, UroGen remains one of Superstring's top five holdings, and the key question for investors will be whether UroGen can convert its clinical momentum into a sustainable oncology franchise, especially with UGN-103's patent protection expected to last until 2041.
See More
Superstring Capital Reduces Stake in UroGen Pharma
- Stake Reduction Details: Superstring Capital sold 330,983 shares of UroGen Pharma in Q1, with an estimated transaction value of $6.64 million, indicating a potential decrease in confidence in the company.
- Position Value Decline: The quarter-end value of Superstring's holdings in UroGen fell by $9.86 million, reflecting the dual impact of trading activity and stock price fluctuations, with total holdings now at 387,371 shares valued at $6.96 million.
- Company Strategy and Market Position: UroGen Pharma focuses on innovative therapies, particularly for non-muscle invasive bladder cancer, and despite the stake reduction, it remains one of Superstring's top five holdings, accounting for about 5%, highlighting its significance in the rapidly growing biotech market.
- Clinical Progress and Investor Interest: UroGen's recently approved bladder cancer therapy ZUSDURI demonstrated a 64.5% probability of three-year disease-free survival, and promising Phase 3 data for UGN-103 is on track for NDA submission in Q3 2026, prompting investors to consider whether the company can leverage clinical momentum into a sustainable oncology franchise.
See More
Healthcare Stocks Rise 0.8% on NYSE Healthcare Index
- Healthcare Sector Recovery: On Wednesday afternoon, the NYSE Healthcare Index rose by 0.8%, indicating a gradual restoration of investor confidence in the healthcare sector, likely driven by an overall improvement in market sentiment.
- Market Rebound Signs: The increase in healthcare stocks suggests that despite economic uncertainties, investors remain optimistic about the long-term growth potential of the healthcare industry, particularly in areas like drug development and medical technology innovation.
- Increased Investor Attention: As the healthcare sector continues to evolve, heightened investor interest may lead to increased capital inflows into this area, further driving stock prices upward.
- Optimistic Industry Outlook: The growth potential of the healthcare sector is attracting more investor attention, especially against the backdrop of rising global health demands, with expectations for increased investments to support innovation and expansion in the future.
See More
Urogen Pharma CMO Mark Schoenberg Sells Shares
- Executive Sell-off: Urogen Pharma's Chief Medical Officer Mark Schoenberg sold 10,000 shares on May 8, 2026, which may indicate a cautious outlook on the company's future performance, potentially negatively impacting investor confidence.
- Market Reaction: Such executive sell-offs are often interpreted by the market as a sign of unease regarding the company's prospects, which could lead to short-term stock price volatility, prompting investors to closely monitor subsequent developments to assess potential risks.
- Shareholding Changes: This sale may affect Schoenberg's ownership stake, and investors should pay attention to any subsequent changes in his holdings to gauge his confidence in the company's future.
- Transparency Concerns: The executive's sell-off raises market concerns about the company's governance transparency, which may lead investors to question the management team's decision-making capabilities.
See More
UroGen Pharma Reports Strong Q1 2026 Earnings with Significant ZUSDURI Growth
- ZUSDURI Revenue Surge: UroGen Pharma reported $29.2 million in ZUSDURI revenue for Q1 2026, representing over 100% quarter-over-quarter growth, indicating a significant increase in market acceptance and suggesting substantial future sales potential.
- Increase in Prescribers: By the end of Q1, UroGen had 256 unique prescribers, up from 102 at year-end, with repeat prescribers rising from 32 to 103, demonstrating accelerated market penetration and growing physician engagement.
- Improved Financial Performance: The company achieved total revenue of $51 million in Q1, a substantial increase from $20.3 million in the same quarter of 2025, although it reported a net loss of $23.6 million, which is an improvement from a loss of $43.8 million a year earlier, indicating a gradual financial recovery.
- Optimistic Future Outlook: Management expects continued strong growth throughout 2026, although formal sales guidance for ZUSDURI is not provided; however, net product revenues for JELMYTO are projected to be between $97 million and $101 million, reflecting confidence in the product line.
See More
UroGen Pharma Q1 Earnings Beat Expectations
- Earnings Highlights: UroGen Pharma reported a Q1 GAAP EPS of -$0.47, beating expectations by $0.01, indicating a slight improvement in financial performance despite ongoing losses.
- Revenue Surge: The company achieved Q1 revenue of $51 million, reflecting a remarkable 151.2% year-over-year increase, surpassing estimates by $6.18 million, which underscores strong market demand for its products.
- Future Guidance: UroGen expects net product revenue for JELMYTO in 2026 to range between $97 million and $101 million, implying a year-over-year growth rate of approximately 3% to 7% over the $94 million reported in 2025, indicating a stable market outlook.
- Expense Projections: The company anticipates full-year 2026 operating expenses to be between $240 million and $250 million, including non-cash share-based compensation expenses of $20 million to $24 million, highlighting the cost pressures associated with business expansion.
See More
